Why are orphan drugs so expensive?

Current methods to determine the right value for orphan drugs remain controversial, yet the fast-tracking of new therapies marks a big step forward for the industry

Rare diseases require radical new funding methods

Devising funding strategies to develop drugs for the treatment of rare diseases remains a challenge as patient groups are often too small

Repurposing drugs with anti-cancer side effects

Although there have been many dramatic breakthroughs in chemotherapy, often guided by genomics, in immunotherapy, radiotherapy and surgery, there are still many cancer patients who progress in spite of these advances

‘Old’ drugs for new treatments

An unprecedented choice of treatments may soon be available in the battle against multiple sclerosis, as John Illman reports